136 related articles for article (PubMed ID: 21192844)
1. MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer.
Cheng JP; Yan Y; Wang XY; Lu YL; Yuan YH; Jia J; Ren J
Chin J Cancer; 2011 Jan; 30(1):54-61. PubMed ID: 21192844
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer.
Sinn BV; von Minckwitz G; Denkert C; Eidtmann H; Darb-Esfahani S; Tesch H; Kronenwett R; Hoffmann G; Belau A; Thommsen C; Holzhausen HJ; Grasshoff ST; Baumann K; Mehta K; Dietel M; Loibl S
Ann Oncol; 2013 Sep; 24(9):2316-24. PubMed ID: 23661292
[TBL] [Abstract][Full Text] [Related]
3. [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
Yu J; DI Lj; Song Gh; Che L; Jiang Hf; Zhu Yl; Liang X; Jia J; Zhang J; Yang Hb; Wang Xl; Zhou Xn; Ren J
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):151-6. PubMed ID: 21321641
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Wang XX; Zhou ZM; Yuan ZY; Zhang DS; Shi YX; Jiang WQ
Ai Zheng; 2007 Apr; 26(4):407-10. PubMed ID: 17430662
[TBL] [Abstract][Full Text] [Related]
5. [Detection and clinical value of epithelial cellular adhesion molecule (EpCAM) mRNA positive circulating tumor cells in metastatic breast cancer].
Yan Y; Cheng JP; Di LJ; Song GH; Ren J
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 44(2):275-80. PubMed ID: 22517003
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of MUC1 and c-Met RT-PCR detection of circulating tumor cells in patients with gastric carcinoma.
Uen YH; Lin SR; Wu CH; Hsieh JS; Lu CY; Yu FJ; Huang TJ; Wang JY
Clin Chim Acta; 2006 May; 367(1-2):55-61. PubMed ID: 16403482
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
[TBL] [Abstract][Full Text] [Related]
8. Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction.
de Cremoux P; Extra JM; Denis MG; Pierga JY; Bourstyn E; Nos C; Clough KB; Boudou E; Martin EC; Müller A; Pouillart P; Magdelénat H
Clin Cancer Res; 2000 Aug; 6(8):3117-22. PubMed ID: 10955792
[TBL] [Abstract][Full Text] [Related]
9. Identification of carcinoma cells in peripheral blood samples of patients with advanced breast carcinoma using RT-PCR amplification of CK7 and MUC1.
Felton T; Harris GC; Pinder SE; Snead DR; Carter GI; Bell JA; Haines A; Kollias J; Robertson JF; Elston CW; Ellis IO
Breast; 2004 Feb; 13(1):35-41. PubMed ID: 14759714
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer.
Jing X; Liang H; Hao C; Yang X; Cui X
Oncol Rep; 2019 Feb; 41(2):801-810. PubMed ID: 30483806
[TBL] [Abstract][Full Text] [Related]
11. CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.
Zhou X; Qiao G; Wang X; Song Q; Morse MA; Hobeika A; Gwin WR; Ren J; Lyerly HK
Cancer Chemother Pharmacol; 2018 Feb; 81(2):365-372. PubMed ID: 29242966
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.
Tewes M; Aktas B; Welt A; Mueller S; Hauch S; Kimmig R; Kasimir-Bauer S
Breast Cancer Res Treat; 2009 Jun; 115(3):581-90. PubMed ID: 18679793
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer.
Ibrahim NK; Yariz KO; Bondarenko I; Manikhas A; Semiglazov V; Alyasova A; Komisarenko V; Shparyk Y; Murray JL; Jones D; Senderovich S; Chau A; Erlandsson F; Acton G; Pegram M
Clin Cancer Res; 2011 Nov; 17(21):6822-30. PubMed ID: 21878535
[TBL] [Abstract][Full Text] [Related]
14. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
Smith IE; Pierga JY; Biganzoli L; Cortés-Funes H; Thomssen C; Pivot X; Fabi A; Xu B; Stroyakovskiy D; Franke FA; Kaufman B; Mainwaring P; Pienkowski T; De Valk B; Kwong A; González-Trujillo JL; Koza I; Petrakova K; Pereira D; Pritchard KI;
Ann Oncol; 2011 Mar; 22(3):595-602. PubMed ID: 20819780
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Wardley AM; Pivot X; Morales-Vasquez F; Zetina LM; de Fátima Dias Gaui M; Reyes DO; Jassem J; Barton C; Button P; Hersberger V; Torres AA
J Clin Oncol; 2010 Feb; 28(6):976-83. PubMed ID: 20038734
[TBL] [Abstract][Full Text] [Related]
16. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
Yie SM; Luo B; Ye NY; Xie K; Ye SR
Clin Exp Metastasis; 2006; 23(5-6):279-89. PubMed ID: 17086357
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Drooger JC; van Tinteren H; de Groot SM; Ten Tije AJ; de Graaf H; Portielje JE; Jager A; Honkoop A; Linn SC; Kroep JR; Erdkamp FL; Hamberg P; Imholz AL; van Rossum-Schornagel QC; Heijns JB; van Leeuwen-Stok AE; Sleijfer S
Cancer; 2016 Oct; 122(19):2961-70. PubMed ID: 27315546
[TBL] [Abstract][Full Text] [Related]
18. Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy.
Hashimoto K; Yonemori K; Katsumata N; Shimizu C; Hirakawa A; Hirata T; Kouno T; Tamura K; Ando M; Fujiwara Y
Ann Oncol; 2010 Nov; 21(11):2195-2200. PubMed ID: 20444847
[TBL] [Abstract][Full Text] [Related]
19. Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification.
Noguchi S; Aihara T; Motomura K; Inaji H; Imaoka S; Koyama H
Am J Pathol; 1996 Feb; 148(2):649-56. PubMed ID: 8579127
[TBL] [Abstract][Full Text] [Related]
20. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
